Becton, Dickinson and Company (NYSE:BDX - Free Report) had its target price reduced by Barclays from $261.00 to $241.00 in a research report report published on Tuesday morning,Benzinga reports. Barclays currently has an overweight rating on the medical instruments supplier's stock.
A number of other analysts also recently issued reports on BDX. Piper Sandler downgraded shares of Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and dropped their price objective for the stock from $260.00 to $185.00 in a report on Friday, May 2nd. Wells Fargo & Company lowered Becton, Dickinson and Company from an "overweight" rating to an "equal weight" rating in a research report on Thursday, May 1st. William Blair downgraded Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a report on Thursday, May 1st. Stifel Nicolaus dropped their target price on Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Finally, Raymond James cut Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research note on Friday, May 2nd. Eight research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of "Hold" and an average target price of $219.22.
Get Our Latest Stock Report on Becton, Dickinson and Company
Becton, Dickinson and Company Stock Performance
Shares of NYSE BDX traded up $0.20 during trading on Tuesday, reaching $170.86. 2,463,139 shares of the stock traded hands, compared to its average volume of 1,935,193. The stock has a market capitalization of $48.97 billion, a P/E ratio of 28.38, a price-to-earnings-growth ratio of 1.63 and a beta of 0.31. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63. The company has a 50-day moving average of $190.30 and a 200-day moving average of $215.85. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, beating the consensus estimate of $3.28 by $0.07. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. The firm had revenue of $5.27 billion for the quarter, compared to analysts' expectations of $5.35 billion. During the same period in the prior year, the business posted $3.17 earnings per share. The company's revenue was up 4.5% on a year-over-year basis. Analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.
Becton, Dickinson and Company Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 30th. Shareholders of record on Monday, June 9th will be issued a $1.04 dividend. The ex-dividend date of this dividend is Monday, June 9th. This represents a $4.16 annualized dividend and a yield of 2.43%. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 79.39%.
Insiders Place Their Bets
In related news, EVP Richard Byrd sold 459 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $230.00, for a total value of $105,570.00. Following the completion of the transaction, the executive vice president now directly owns 6,952 shares in the company, valued at $1,598,960. This trade represents a 6.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP David Shan sold 1,166 shares of Becton, Dickinson and Company stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total transaction of $199,607.54. Following the transaction, the executive vice president now owns 4,575 shares of the company's stock, valued at $783,194.25. The trade was a 20.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 4,044 shares of company stock worth $836,000. Company insiders own 0.36% of the company's stock.
Institutional Investors Weigh In On Becton, Dickinson and Company
A number of institutional investors have recently modified their holdings of BDX. Brighton Jones LLC grew its position in Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock valued at $401,000 after purchasing an additional 877 shares during the last quarter. E. Ohman J or Asset Management AB increased its position in shares of Becton, Dickinson and Company by 13.4% during the fourth quarter. E. Ohman J or Asset Management AB now owns 176,097 shares of the medical instruments supplier's stock valued at $39,951,000 after acquiring an additional 20,859 shares in the last quarter. Phraction Management LLC raised its holdings in Becton, Dickinson and Company by 7.2% in the 4th quarter. Phraction Management LLC now owns 47,021 shares of the medical instruments supplier's stock worth $10,668,000 after acquiring an additional 3,138 shares during the last quarter. Savant Capital LLC raised its holdings in Becton, Dickinson and Company by 85.9% in the 4th quarter. Savant Capital LLC now owns 14,628 shares of the medical instruments supplier's stock worth $3,319,000 after acquiring an additional 6,759 shares during the last quarter. Finally, Vest Financial LLC lifted its position in Becton, Dickinson and Company by 15.1% in the 4th quarter. Vest Financial LLC now owns 237,853 shares of the medical instruments supplier's stock valued at $53,962,000 after acquiring an additional 31,141 shares in the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.
About Becton, Dickinson and Company
(
Get Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
See Also
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
